Comparing DAPSA, DAPSA28 and DAS28-CRP in patients with psoriatic arthritis initiating a first TNF-inhibitor across nine European countries
04/07/2024
Linde L, Georgiadis S, Ørnbjerg LM, Rasmussen SH, Michelsen B, Askling J, Di Giuseppe D, Wallman JK, Závada J, Pavelka K, Bernardes M, Matos CO, Glintborg B, Loft AG, Nordström D, Kuusalo L, Möller B, Nissen MJ, Codreanu C, Mogosan C, Gudbjornsson B, Love TJ, Akleylek C, Iannone F, Kvien TK, Rotar Z, Castrejon I, Macfarlane GJ, Hetland ML, Østergaard M.
Linde L, Georgiadis S, Ørnbjerg LM, Rasmussen SH, Michelsen B, Askling J, Di Giuseppe D, Wallman JK, Závada J, Pavelka K, Bernardes M, Matos CO, Glintborg B, Loft AG, Nordström D, Kuusalo L, Möller B, Nissen MJ, Codreanu C, Mogosan C, Gudbjornsson B, Love TJ, Akleylek C, Iannone F, Kvien TK, Rotar Z, Castrejon I, Macfarlane GJ, Hetland ML, Østergaard M. Comparing DAPSA, DAPSA28 and DAS28-CRP in patients with psoriatic arthritis initiating a first TNF-inhibitor across nine European countries. Arthritis Care Res (Hoboken). 2024 Jun 26. doi: 10.1002/acr.25396. Epub ahead of print. PMID: 38926900.
doi: 10.1002/acr.25396